A Phase 3 interventional study of enoxaparin and Physical prophylaxis in Abdominal Neoplasms, sponsored by Sanofi. Completed at 1 site in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-04-05.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery. The secondary objective is evaluate the incidence of adverse events of enoxaparin in these patients.
67 studies on the registry are indexed under Abdominal Neoplasms; 18 are open to participants now.
This study's enrollment of 151 is above the median of 74 across 49 interventional studies indexed under Abdominal Neoplasms.
Browse Abdominal Neoplasms studies →Sanofi is the lead sponsor of 1,508 studies on the registry; 90 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 118 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Enoxaparin
Drug: enoxaparin
Intermittent Pneumatic Compression (IPC)
Other: Physical prophylaxis
20 mg twice a day
Venous thromboembolism incidence
Time frame: 28 days
Incidence of deep vein thrombosis, pulmonary thromboembolism, and venous thromboembolism incidence except patients with thrombus only in muscle veins, and incidence of proximal vein thrombosis
Time frame: 28 days
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi